Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and Efficacy of XZB-0004 in Solid Tumours
NCT05772455Phase 1Recruiting
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- Mar 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of slc-391 in solid tumor, non-small cell lung cancer (NSCLC), urothelial carcinoma (UC) and 1 more (2 arms), sponsored by Xuanzhu Biopharmaceutical. Primary endpoints: Maximum Tolerated Dose up to 3 weeks, Recommended Phase 2 Dose up to 3 weeks and 1 more. Started Mar 2023; status: recruiting.
02
Drugs
slc-391
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)urothelial carcinoma (UC)melanoma
Beyond the preview
Go deeper on NCT05772455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05772455.